Range Low Price High Price Comment
30 days $0.87 $1.55 Monday, 29th Apr 2024 ADAP stock ended at $1.15. This is 6.98% more than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 11.11% from a day low at $1.08 to a day high of $1.20.
90 days $0.762 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Jan 29, 2016 $7.07 $7.07 $7.07 $7.07 238 100
Jan 28, 2016 $7.23 $7.23 $7.23 $7.23 352 200
Jan 27, 2016 $7.76 $7.76 $7.76 $7.76 263 400
Jan 26, 2016 $8.34 $8.34 $8.34 $8.34 168 900
Jan 25, 2016 $8.50 $8.50 $8.50 $8.50 180 200
Jan 22, 2016 $8.81 $8.81 $8.81 $8.81 157 100
Jan 21, 2016 $8.02 $8.02 $8.02 $8.02 218 300
Jan 20, 2016 $8.05 $8.05 $8.05 $8.05 486 200
Jan 19, 2016 $7.62 $7.62 $7.62 $7.62 297 800
Jan 15, 2016 $7.66 $7.66 $7.66 $7.66 414 100
Jan 14, 2016 $7.55 $7.55 $7.55 $7.55 673 200
Jan 13, 2016 $7.18 $7.18 $7.18 $7.18 546 900
Jan 12, 2016 $8.51 $8.51 $8.51 $8.51 774 800
Jan 11, 2016 $9.42 $9.42 $9.42 $9.42 820 500
Jan 08, 2016 $10.53 $10.53 $10.53 $10.53 544 700
Jan 07, 2016 $10.65 $10.65 $10.65 $10.65 825 800
Jan 06, 2016 $11.68 $11.68 $11.68 $11.68 809 700
Jan 05, 2016 $12.29 $12.29 $12.29 $12.29 551 600
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT